Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Collaboration

Year: 2024

Puig, N; Agulló, C; Contreras, T; Cedena, MT; Martínez-López, J; Oriol, A; Blanchard, M.J.; Ríos, R; Inigo, MB; Sureda, A; Lakhwani, S; de la Rubia, J; González-Calle, V; Cabins, V; Palomera, L; Moraleda, JM; Bargay, J; Castro, S; Rosiñol, L; Bladé, J; San-Miguel, JF; Moraleda, JJ; Pava, B; Mateos, MV

Title: BLOOD

• D1